Selected Publications
Selected Publications
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA†, Ruscetti M†. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30;122(39):e2514948122. doi: 10.1073/pnas.2514948122. Epub 2025 Sep 22. PMID: 40982692.
Murphy KC, DeMarco KD, Zhou L, Peura J, Giwa HK, Lopez-Diaz Y, Ho YJ, Li J, Bai S, Simin K, Zhu LJ, Pitarresi JR, Mercurio AM, Ruscetti M. MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T Cell and Immunotherapy Responses in Prostate Cancer. Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-2532. Epub ahead of print. PMID: 40899986.
Zhou L, Ma B, Ruscetti M. Cellular senescence offers distinct immunological vulnerabilities in cancer. Trends Cancer. 2025 Apr;11(4):334-350. PMID: 39732594.
Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdhury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU†, Ruscetti M†. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024 Aug 28;16(762): eadj9366. PMID: 39196958.
Alcolea MP, Alonso-Curbelo D, Ambrogio C, Bullman S, Correia AL, Ernst A, Halbrook CJ, Kelly GL, Lund AW, Quail DF, Ruscetti M, Shema E, Stromnes IM, Tam WL. Cancer Hallmarks: Piecing the Puzzle Together. Cancer Discov. 2024 Apr 4;14(4): 674–682. PMID: 38571410.
Murphy, KC and Ruscetti, M. Advances in Making Cancer Mouse Models More Accessible and Informative Through Non-Germline Genetic Engineering. Cold Spring Harb Perspect Med. 2023 Jun 05.
Zhou, L. & Ruscetti, M. Senescent macrophages: A new “old” player in lung cancer development. Cancer Cell. 2023 07 10; 41(7):1201-1203.
Chibaya L, Murphy KC, DeMarco KD, Gopalan S, Liu H, Parikh CN, Lopez-Diaz Y, Faulkner M, Li J, Morris JP, Ho YJ, Chana SK, Simon J, Luan W, Kulick A, de Stanchina E, Simin K, Zhu LJ, Fazzio TG, Lowe SW, Ruscetti M. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Nature Cancer. 2023 06; 4(6):872-892.
Chibaya, L*, Snyder, J*, and Ruscetti, M. Senescence and the tumor-immune landscape: Implications for cancer immunotherapy. Semin Cancer Biol. 2022 Nov; 86(Pt 3):827-845.
Leibold, J*, Ruscetti, M*, Chao, Zhen*, Ho, YJ, Baslan, T, Zhou, M, Abida, W, Feucht, J, Han, T, Barriga, FM, Tsanov, KM, Zamechek, L, Kulick, A, Amor, C, Tian, S, Salgado, NR, Sánchez-Rivera, FJ, de Stanchina, E, Wilkinson, JE, Dow, LE, Abate-Shen, C, Sawyers, CL, and Lowe, SW. Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis. Cancer Discovery. 2020 07; 10(7):1038-1057.
Ruscetti, M*, Morris, JP IV*, Mezzadra, R*, Russell, J, Leibold, J, Romesser, PB, Simon, J, Kulick, A, Ho, YJ, Fennel, M, Li, J, Norgard, RJ, Wilkinson, JE, Alonso-Curbelo, D, Sridharan, R, Heller, D, de Stanchina, E, Stanger, BZ, Sherr, CJ, and Lowe, SW. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell. 2020 04 16; 181(2):424-441.e21.
Ruscetti, M*, Leibold, J*, Bott, M*, Fennell, M, Kulick, A, Salgado, NR, Chen, CC, Ho, YJ, Sanchez-Rivera, FJ, Feucht, J, Baslan, T, Tian, S, Chen, HA, Romesser, PB, Poirier, JT, Rudin, CM, de Stanchina, E, Manchado-Robles, E, Sherr, CJ, and Lowe, SW. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018 12 21; 362(6421):1416-1422.